Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction

Sergiy M Koval; Iryna O Snihurska; Kostiantyn O Yushko; Olga V Mysnychenko; Marina Yu Penkova; Olga M Lytvynova; Alexander E Berezin; Vadym S Lytvynov

doi:10.3389/fcvm.2020.00104

Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction

Front Cardiovasc Med. 2020 Jul 7:7:104. doi: 10.3389/fcvm.2020.00104. eCollection 2020.

Authors

Sergiy M Koval¹, Iryna O Snihurska¹, Kostiantyn O Yushko¹, Olga V Mysnychenko¹, Marina Yu Penkova¹, Olga M Lytvynova², Alexander E Berezin³, Vadym S Lytvynov⁴

Affiliations

¹ Department of Arterial Hypertension and Prevention of Its Complications, Government Institution "L.T. Malaya Therapy National Institute of the National Academy of Medical Science of Ukraine, " Kharkiv, Ukraine.
² Department of Laboratory Diagnostics, National University of Pharmacy, Kharkiv, Ukraine.
³ Internal Medicine Department, Zaporizhia State Medical University, Zaporizhzhia, Ukraine.
⁴ Department of Therapy, Rheumatology and Clinical Pharmacology, Kharkiv Medical Academy of Postgraduate Education (KhMAPE), Kharkiv, Ukraine.

Abstract

Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). Materials and Methods: A total of 48 patients with grade 2-3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA). Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = -0.40, p = 0.003 and R = -0.35, p = 0.04, respectively). Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD.

Keywords: arterial hypertension; epigenetics; hypertensive heart disease; left ventricular diastolic dysfunction; microRNA-133a.